The use of immune checkpoint blockade (ICB) therapies, including antibodies targeting programmed cell death 1 (PD-1) and cytotoxic T-Lymphocyte-associated Protein 4 (CTLA-4), alone or in combination, has marked a significant advancement in the treatment of malignant tumors like melanoma. Here, CTLA4 is linked to melanoma.